KR102896955B1 - 암의 검사 방법 - Google Patents
암의 검사 방법Info
- Publication number
- KR102896955B1 KR102896955B1 KR1020227012018A KR20227012018A KR102896955B1 KR 102896955 B1 KR102896955 B1 KR 102896955B1 KR 1020227012018 A KR1020227012018 A KR 1020227012018A KR 20227012018 A KR20227012018 A KR 20227012018A KR 102896955 B1 KR102896955 B1 KR 102896955B1
- Authority
- KR
- South Korea
- Prior art keywords
- molecule
- bc2lcn
- serpina3
- cancer
- gal3bp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G01N33/574—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/548—Carbohydrates, e.g. dextran
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4724—Lectins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
- G01N2333/8121—Serpins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
- G01N2333/8121—Serpins
- G01N2333/8125—Alpha-1-antitrypsin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2019-187197 | 2019-10-11 | ||
| JP2019187197 | 2019-10-11 | ||
| PCT/JP2020/038300 WO2021070934A1 (ja) | 2019-10-11 | 2020-10-09 | がんの検査方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220079855A KR20220079855A (ko) | 2022-06-14 |
| KR102896955B1 true KR102896955B1 (ko) | 2025-12-05 |
Family
ID=75438180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227012018A Active KR102896955B1 (ko) | 2019-10-11 | 2020-10-09 | 암의 검사 방법 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12618842B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4043881A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7656829B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102896955B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114556101B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021070934A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022182394A (ja) * | 2021-05-28 | 2022-12-08 | 独立行政法人国立病院機構 | 抗原固相化デバイス |
| WO2025187809A1 (ja) * | 2024-03-08 | 2025-09-12 | 富士フイルム株式会社 | 検出対象物質を免疫学的に検出する方法、非特異反応を抑制する方法、フコース含有組成物、および試薬キット |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017061449A1 (ja) * | 2015-10-05 | 2017-04-13 | 国立研究開発法人産業技術総合研究所 | がん細胞の検出方法、がん細胞内に物質を導入するための試薬、及びがん治療用組成物 |
| WO2018190357A1 (ja) * | 2017-04-11 | 2018-10-18 | 国立研究開発法人産業技術総合研究所 | レクチンの固定化方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596476B1 (en) * | 1989-12-22 | 2003-07-22 | Abbott Laboratories | Hepatitis C assay |
| JP5977743B2 (ja) | 2011-06-15 | 2016-08-24 | 三洋化成工業株式会社 | 磁性シリカ粒子を用いた測定方法及び該測定方法用試薬 |
| WO2013172105A1 (ja) * | 2012-05-18 | 2013-11-21 | 日東紡績株式会社 | 膵臓癌を検出するためのマーカー |
| WO2014126146A1 (ja) | 2013-02-14 | 2014-08-21 | 独立行政法人産業技術総合研究所 | 未分化細胞除去方法 |
| JP7386647B2 (ja) | 2018-08-13 | 2023-11-27 | 東ソー株式会社 | 糖鎖への親和性が向上したフコース結合性タンパク質、およびその製造方法 |
-
2020
- 2020-10-09 EP EP20873535.7A patent/EP4043881A4/en active Pending
- 2020-10-09 CN CN202080071169.XA patent/CN114556101B/zh active Active
- 2020-10-09 WO PCT/JP2020/038300 patent/WO2021070934A1/ja not_active Ceased
- 2020-10-09 JP JP2021551720A patent/JP7656829B2/ja active Active
- 2020-10-09 KR KR1020227012018A patent/KR102896955B1/ko active Active
-
2022
- 2022-04-11 US US17/717,764 patent/US12618842B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017061449A1 (ja) * | 2015-10-05 | 2017-04-13 | 国立研究開発法人産業技術総合研究所 | がん細胞の検出方法、がん細胞内に物質を導入するための試薬、及びがん治療用組成物 |
| WO2018190357A1 (ja) * | 2017-04-11 | 2018-10-18 | 国立研究開発法人産業技術総合研究所 | レクチンの固定化方法 |
Non-Patent Citations (2)
| Title |
|---|
| Laubli Heinz et al, Journal of Biological Chemistry (2014.11.28.), vol 289.48, pp 33481-33491.* |
| Zeng Xuemei et al, Journal of Proteome Research (2010.10.08.), vol 9.12, pp 6440-6449.* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220079855A (ko) | 2022-06-14 |
| JP7656829B2 (ja) | 2025-04-04 |
| EP4043881A1 (en) | 2022-08-17 |
| WO2021070934A1 (ja) | 2021-04-15 |
| EP4043881A4 (en) | 2022-11-23 |
| US12618842B2 (en) | 2026-05-05 |
| US20220236275A1 (en) | 2022-07-28 |
| CN114556101A (zh) | 2022-05-27 |
| JPWO2021070934A1 (cg-RX-API-DMAC7.html) | 2021-04-15 |
| CN114556101B (zh) | 2025-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102356316B (zh) | 肝内胆管癌的检出、辨别方法 | |
| EP1137943B1 (en) | Cancer detection method and reagents | |
| JP7490007B2 (ja) | レクチンベースのがんの診断 | |
| AU2013210776B2 (en) | Biomarkers for gastric cancer and uses thereof | |
| WO2022063156A1 (zh) | 乳腺癌的生物标志物及其应用 | |
| EP2851688B1 (en) | Use of glycoprotein C4BPA as marker for detecting pancreatic cancer | |
| WO2022083673A1 (zh) | 食管癌的生物标志物及其应用 | |
| JP2002532686A5 (cg-RX-API-DMAC7.html) | ||
| WO2022083603A1 (zh) | 半胱氨酸蛋白酶抑制剂与Cathepsin复合物作为肿瘤诊断标志物的应用 | |
| US20030138860A1 (en) | Cancer detection methods and reagents | |
| WO2022083586A1 (zh) | 半胱氨酸蛋白酶抑制剂sn与cathepsin l1复合物作为胃癌诊断标志物的应用 | |
| US12618842B2 (en) | Cancer test method | |
| KR101144324B1 (ko) | 대장암 예후진단용 단백질 마커 디펜신?5와 rod1단백질의 조합 및 이들 각각에 대한 항체를 포함하는 대장암 예후진단키트 | |
| Fania et al. | A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification | |
| US20180188255A1 (en) | Method for the in vitro diagnosis of pancreatic ductal adenocarcinoma or for determining the predisposition to pancreatic ductal adenocarcinoma | |
| WO2021246153A1 (ja) | 膵臓がんの検出方法及び検出試薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D13-X000 | Search requested |
St.27 status event code: A-1-2-D10-D13-srh-X000 |
|
| D14-X000 | Search report completed |
St.27 status event code: A-1-2-D10-D14-srh-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P22-X000 | Classification modified |
St.27 status event code: A-4-4-P10-P22-nap-X000 |